BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34419484)

  • 21. Hepatitis B virus sensitivity to interferon-α in hepatocytes is more associated with cellular interferon response than with viral genotype.
    Shen F; Li Y; Wang Y; Sozzi V; Revill PA; Liu J; Gao L; Yang G; Lu M; Sutter K; Dittmer U; Chen J; Yuan Z
    Hepatology; 2018 Apr; 67(4):1237-1252. PubMed ID: 29059468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The retinoic acid receptor (RAR) α-specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA.
    Nkongolo S; Nußbaum L; Lempp FA; Wodrich H; Urban S; Ni Y
    Antiviral Res; 2019 Aug; 168():146-155. PubMed ID: 31018112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new strategy to identify hepatitis B virus entry inhibitors by AlphaScreen technology targeting the envelope-receptor interaction.
    Saso W; Tsukuda S; Ohashi H; Fukano K; Morishita R; Matsunaga S; Ohki M; Ryo A; Park SY; Suzuki R; Aizaki H; Muramatsu M; Sureau C; Wakita T; Matano T; Watashi K
    Biochem Biophys Res Commun; 2018 Jun; 501(2):374-379. PubMed ID: 29730285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
    Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
    Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
    Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
    J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and evaluation of pentacyclic triterpenoids conjugates as novel HBV entry inhibitors targeting NTCP receptor.
    Chen Y; Duan M; Wang X; Xu J; Tian S; Xu X; Duan A; Mahal A; Zhu Y; Zhu Q
    Bioorg Chem; 2024 Jun; 147():107385. PubMed ID: 38663255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
    Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Glebe D; Baringhaus KH; Geyer J
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33921515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual Agonist of Farnesoid X Receptor and Takeda G Protein-Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo.
    Ito K; Okumura A; Takeuchi JS; Watashi K; Inoue R; Yamauchi T; Sakamoto K; Yamashita Y; Iguchi Y; Une M; Wakita T; Umezawa K; Yoneda M
    Hepatology; 2021 Jul; 74(1):83-98. PubMed ID: 33434356
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation and identification of hepatitis B virus entry inhibitors using HepG2 cells overexpressing a membrane transporter NTCP.
    Iwamoto M; Watashi K; Tsukuda S; Aly HH; Fukasawa M; Fujimoto A; Suzuki R; Aizaki H; Ito T; Koiwai O; Kusuhara H; Wakita T
    Biochem Biophys Res Commun; 2014 Jan; 443(3):808-13. PubMed ID: 24342612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification and characterization of a novel hepatitis B virus pregenomic RNA encapsidation inhibitor.
    Jo E; Ryu DK; König A; Park S; Cho Y; Park SH; Kim TH; Yoon SK; Ryu WS; Cechetto J; Windisch MP
    Antiviral Res; 2020 Mar; 175():104709. PubMed ID: 31940474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term
    Lowjaga KAAT; Kirstgen M; Müller SF; Goldmann N; Lehmann F; Glebe D; Geyer J
    Am J Physiol Gastrointest Liver Physiol; 2021 Jan; 320(1):G66-G80. PubMed ID: 33174454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemical array system, a platform to identify novel hepatitis B virus entry inhibitors targeting sodium taurocholate cotransporting polypeptide.
    Kaneko M; Futamura Y; Tsukuda S; Kondoh Y; Sekine T; Hirano H; Fukano K; Ohashi H; Saso W; Morishita R; Matsunaga S; Kawai F; Ryo A; Park SY; Suzuki R; Aizaki H; Ohtani N; Sureau C; Wakita T; Osada H; Watashi K
    Sci Rep; 2018 Feb; 8(1):2769. PubMed ID: 29426822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes.
    Lucifora J; Esser K; Protzer U
    Antiviral Res; 2013 Feb; 97(2):195-7. PubMed ID: 23266293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
    Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
    Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
    Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
    J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficient Inhibition of Hepatitis B Virus Infection by a preS1-binding Peptide.
    Ye X; Zhou M; He Y; Wan Y; Bai W; Tao S; Ren Y; Zhang X; Xu J; Liu J; Zhang J; Hu K; Xie Y
    Sci Rep; 2016 Jul; 6():29391. PubMed ID: 27384014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Retinoic Acid Receptor Agonists as Potent Hepatitis B Virus Inhibitors via a Drug Repurposing Screen.
    Li B; Wang Y; Shen F; Wu M; Li Y; Fang Z; Ye J; Wang L; Gao L; Yuan Z; Chen J
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rimonabant suppresses RNA transcription of hepatitis B virus by inhibiting hepatocyte nuclear factor 4α.
    Sato A; Ono C; Tamura T; Mori H; Izumi T; Torii S; Fauzyah Y; Yamamoto T; Morioka Y; Okuzaki D; Fukuhara T; Matsuura Y
    Microbiol Immunol; 2020 May; 64(5):345-355. PubMed ID: 31981244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amentoflavone inhibits hepatitis B virus infection via the suppression of preS1 binding to host cells.
    Aoki-Utsubo C; Indrasetiawan P; Fukano K; Muramatsu M; Artanti N; Hanafi M; Hotta H; Kameoka M
    Microbiol Immunol; 2023 Jun; 67(6):281-292. PubMed ID: 36929353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.